Table 2.
Neurologic clinical manifestations.
| Neurological symptoms | n = 45 | % |
|---|---|---|
| Paresthesia | 40 | 88.9 |
| Numbness | 39 | 86.7 |
| Dizziness | 39 | 86.7 |
| Headache | 36 | 80 |
| Subjective cognitive decline | 31 | 68.9 |
| Subjective weakness | 25 | 55.6 |
| Imbalance | 19 | 42.2 |
| Neurological conditions diagnosed | n = 45 | % |
| Peripheral neuropathya | 39 | 86.7 |
| Small fiber neuropathyb | 8 | 17.8 |
| Dysautonomiac | 10 | 22.2 |
| Cognitive impairmentd | 12 | 26.7 |
| Trigeminal neuralgia | 3 | 6.7 |
| Electroencephalogram abnormalitye | 2 | 4.4 |
| Myelopathyf | 1 | 2.2 |
| Transient ischemic attackg | 1 | 2.2 |
Six patients had sensorimotor neuropathy and 33 had sensory neuropathy.
Six patients showed positive skin biopsy. One patient was diagnosed based on clinical symptoms, evidence of small fiber neuropathy on a quantitative sensory test, and a normal nerve conduction test. One patient was diagnosed based on clinical symptoms, sudomotor dysfunction on autonomic tests, and a normal nerve conduction test.
Ten patients were diagnosed using an autonomic test.
Montreal Cognitive Assessment (MoCA) score ≤ 25/30. Of the 45 patients included in this study, 22 underwent MoCA testing.
One patient had intermittent irregular delta activity in the left anterior-midtemporal region. One patient had intermittent focal theta to delta slowing in the left frontotemporal region.
Cervical myelopathy with position sense loss.
Likely due to a hypercoagulable state of unknown origin.